MAPK3 and prostate carcinoma: This observation can be potentially explained by the ability of CuC1 to inhibit ERK1/2 and p38 MAPK pathways, which are known to be over-activated in the docetaxel-resistant prostate cancer cells and contribute to their drug resistance57.